FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595804776> ?p ?o ?g. }

• W2595804776 abstract "Abstract Acute graft-versus-host disease (aGVHD) develops in more than half of patients after allogeneic hematopoietic cell transplantation (allo-HCT) despite poly-pharmacy immunoprophylaxis. Importantly, the dysregulated pathways responsible for this breakthrough disease remain largely unidentified. Thus, the discovery of these pathways represents one of the critical challenges for the field of allo-HCT. To address these needs, we have developed a model of aGVHD in rhesus macaques, which allows us to study the mechanisms of aGVHD both in its untreated state and in a variety of immunoprophylactic settings. Using a systems-based approach, we have created both a multiparameter flow cytometric and transcriptomic map of the immune landscape of aGVHD in allo-HCT recipients, in comparison to two critical control groups: (1) healthy untransplanted controls, and (2) those receiving autologous transplantation. We find that recipients of allo-HCT receiving 1) no immunoprophylaxis 2) monotherapy with CTLA4Ig or 3) monotherapy with sirolimus develop early fulminant aGVHD with multi-organ disease (Figure 1a-grouped as 'Primary GVHD'). The immunophenotype of T cells from the Primary GVHD cohort exhibits an effector/memory phenotype with robust proliferation and acquisition of cytotoxic function. Transcriptomic analysis reveals enrichment of Th1-associated transcripts (IL12RB2, CCR5, CXCR3) as well as programs of proliferation early in the post transplant period (Figure 1b). Flow cytometric data confirms an increase in the number of CD4 and CD8 T cells producing the Th1 cytokine, IFN-g at this time-point (Figure 1c). In contrast, standard-of-care Tacrolimus/Methotrexate (Tac/Mtx) as well as novel CTLA4Ig/sirolimus combination immunoprophylaxis (CoBS) both significantly improved survival of animals after allo-HCT. However, similar to human patients undergoing allo-HCT, these recipients often developed clinical signs of breakthrough aGVHD (starting around day 30 post-transplant) characterized by both gastrointestinal and skin pathology. This cohort was thus termed the Breakthrough GVHD cohort (Figure 1a). Unexpectedly, despite the presence of breakthrough clinical aGVHD, the Tac/Mtx and CoBS cohorts were still able to control programs of T cell proliferation, effector phenotype acquisition and Th1 cytokine skewing. However, both transcriptional and flow cytometric profiles demonstrated enrichment for molecules that reflect Th17/Th22 skewing (RORC, IL17A, AHR, and IL22) (Figure 2a) and production of IL17a (Figure 2b). These results suggest that while current methods of immunoprophylaxis are able to limit both T cell proliferation and Th1 polarization, breakthrough Th17/Th22 pathway activation occurs despite these therapies. These data suggest that emphasis should be placed on exploration of pharmacologic inhibitors of IL17/IL22 for the prevention/treatment of breakthrough aGVHD. Disclosures No relevant conflicts of interest to declare." @default.
• W2595804776 created "2017-03-23" @default.
• W2595804776 creator A5006086815 @default.
• W2595804776 creator A5018050903 @default.
• W2595804776 creator A5020829925 @default.
• W2595804776 creator A5027478389 @default.
• W2595804776 creator A5045561472 @default.
• W2595804776 creator A5058268746 @default.
• W2595804776 creator A5078243560 @default.
• W2595804776 date "2015-12-03" @default.
• W2595804776 modified "2023-10-01" @default.
• W2595804776 title "Th17/Th22 Cells Mediate Breakthrough Graft-Versus-Host-Disease" @default.
• W2595804776 doi "https://doi.org/10.1182/blood.v126.23.1878.1878" @default.
• W2595804776 hasPublicationYear "2015" @default.
• W2595804776 type Work @default.
• W2595804776 sameAs 2595804776 @default.
• W2595804776 citedByCount "0" @default.
• W2595804776 crossrefType "journal-article" @default.
• W2595804776 hasAuthorship W2595804776A5006086815 @default.
• W2595804776 hasAuthorship W2595804776A5018050903 @default.
• W2595804776 hasAuthorship W2595804776A5020829925 @default.
• W2595804776 hasAuthorship W2595804776A5027478389 @default.
• W2595804776 hasAuthorship W2595804776A5045561472 @default.
• W2595804776 hasAuthorship W2595804776A5058268746 @default.
• W2595804776 hasAuthorship W2595804776A5078243560 @default.
• W2595804776 hasConcept C126322002 @default.
• W2595804776 hasConcept C154317977 @default.
• W2595804776 hasConcept C167672396 @default.
• W2595804776 hasConcept C196166836 @default.
• W2595804776 hasConcept C202751555 @default.
• W2595804776 hasConcept C203014093 @default.
• W2595804776 hasConcept C2776090121 @default.
• W2595804776 hasConcept C2777408962 @default.
• W2595804776 hasConcept C2777921159 @default.
• W2595804776 hasConcept C2779972918 @default.
• W2595804776 hasConcept C2781107259 @default.
• W2595804776 hasConcept C2909675724 @default.
• W2595804776 hasConcept C2911091166 @default.
• W2595804776 hasConcept C553184892 @default.
• W2595804776 hasConcept C55493867 @default.
• W2595804776 hasConcept C71924100 @default.
• W2595804776 hasConcept C86803240 @default.
• W2595804776 hasConcept C8891405 @default.
• W2595804776 hasConceptScore W2595804776C126322002 @default.
• W2595804776 hasConceptScore W2595804776C154317977 @default.
• W2595804776 hasConceptScore W2595804776C167672396 @default.
• W2595804776 hasConceptScore W2595804776C196166836 @default.
• W2595804776 hasConceptScore W2595804776C202751555 @default.
• W2595804776 hasConceptScore W2595804776C203014093 @default.
• W2595804776 hasConceptScore W2595804776C2776090121 @default.
• W2595804776 hasConceptScore W2595804776C2777408962 @default.
• W2595804776 hasConceptScore W2595804776C2777921159 @default.
• W2595804776 hasConceptScore W2595804776C2779972918 @default.
• W2595804776 hasConceptScore W2595804776C2781107259 @default.
• W2595804776 hasConceptScore W2595804776C2909675724 @default.
• W2595804776 hasConceptScore W2595804776C2911091166 @default.
• W2595804776 hasConceptScore W2595804776C553184892 @default.
• W2595804776 hasConceptScore W2595804776C55493867 @default.
• W2595804776 hasConceptScore W2595804776C71924100 @default.
• W2595804776 hasConceptScore W2595804776C86803240 @default.
• W2595804776 hasConceptScore W2595804776C8891405 @default.
• W2595804776 hasLocation W25958047761 @default.
• W2595804776 hasOpenAccess W2595804776 @default.
• W2595804776 hasPrimaryLocation W25958047761 @default.
• W2595804776 hasRelatedWork W1979430908 @default.
• W2595804776 hasRelatedWork W1980790815 @default.
• W2595804776 hasRelatedWork W2007762350 @default.
• W2595804776 hasRelatedWork W2008893484 @default.
• W2595804776 hasRelatedWork W2492495869 @default.
• W2595804776 hasRelatedWork W2524053942 @default.
• W2595804776 hasRelatedWork W2549659270 @default.
• W2595804776 hasRelatedWork W2551155978 @default.
• W2595804776 hasRelatedWork W2573857210 @default.
• W2595804776 hasRelatedWork W2586438624 @default.
• W2595804776 hasRelatedWork W2588118813 @default.
• W2595804776 hasRelatedWork W2635692020 @default.
• W2595804776 hasRelatedWork W2761640516 @default.
• W2595804776 hasRelatedWork W2913459776 @default.
• W2595804776 hasRelatedWork W2914529808 @default.
• W2595804776 hasRelatedWork W2914729211 @default.
• W2595804776 hasRelatedWork W2920665535 @default.
• W2595804776 hasRelatedWork W2987958101 @default.
• W2595804776 hasRelatedWork W3128109748 @default.
• W2595804776 hasRelatedWork W3203113184 @default.
• W2595804776 isParatext "false" @default.
• W2595804776 isRetracted "false" @default.
• W2595804776 magId "2595804776" @default.
• W2595804776 workType "article" @default.